Lindsey Norris, MD
Nephrology · Flowood, MSNPI 1306166970
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations.
Across 211 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$516
- Amgen$440
- Fresenius USA Marketing, Inc.$433
- Akebia Therapeutics Inc$330
- Novartis$258
- Aurinia Pharma U.S., Inc.$218
- plus $2K from 18 others
What the payments were for
- Food & beverage$3,89397%
- Education$1193%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 30 | $516 |
| Amgen(2 entities) | 24 | $440 |
| Fresenius USA Marketing, Inc. | 25 | $433 |
| Akebia Therapeutics Inc | 18 | $330 |
| Novartis | 10 | $258 |
| Aurinia Pharma U.S., Inc. | 11 | $218 |
| Calliditas Therapeutics US Inc. | 10 | $203 |
| Vifor Pharma, Inc. | 11 | $197 |
| Bayer | 10 | $194 |
| GSK | 10 | $187 |
| Mallinckrodt Hospital Products Inc. | 6 | $168 |
| Otsuka America Pharmaceutical, Inc. | 8 | $156 |
| OPKO Pharmaceuticals, LLC | 10 | $152 |
| ANI Pharmaceuticals, Inc. | 7 | $139 |
| Ardelyx, Inc. | 4 | $89 |
| Vanda Pharmaceuticals Inc. | 4 | $78 |
| Lilly USA, LLC | 3 | $54 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $44 |
| Boehringer Ingelheim | 2 | $34 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
| Travere Therapeutics, Inc. | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| GRT US Holding, Inc. | 1 | $13 |
How this compares
$4,012 in reported general payments places this provider in the 75th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 108 | $92,855 |
| AuryxiaFerric Citrate | 63 | $79,886 |
| JardianceEmpagliflozin | 106 | $71,229 |
| VelphoroSucroferric Oxyhydroxide | 17 | $42,854 |
| LokelmaSodium Zirconium Cyclosilicate | 34 | $37,330 |
| VeltassaPatiromer Calcium Sorbitex | 14 | $15,822 |
| KerendiaFinerenone | 11 | $8,054 |
| Febuxostat | 43 | $6,707 |
| Sevelamer Carbonate | 61 | $5,813 |
| Mycophenolate Mofetil | 12 | $2,916 |
| Nifedipine ErNifedipine | 88 | $2,890 |
| Potassium Citrate ErPotassium Citrate | 12 | $899 |
| Hydralazine Hcl | 62 | $696 |
| Calcium Acetate | 16 | $641 |
| Furosemide | 134 | $631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $516 | $130,185142 claims |
| Akebia Therapeutics IncAuryxia | $330 | $79,88663 claims |
| Boehringer IngelheimJardiance | $34 | $71,229106 claims |
| Fresenius USA Marketing, Inc.Velphoro | $433 | $42,85417 claims |
| BayerKerendia | $194 | $8,05411 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $139 | $50217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Flowood
- Mohit AhujaFlowood$427K
- Steven WagnerFlowood$6K
- Francis PhillippiFlowood$6K
- Daphne BilbrewFlowood$6K
- Derrick TesseneerFlowood$5K
- Ami PatelFlowood$5K
- Karthikeyan VenkatachalamFlowood$5K
- Lee FergusonFlowood$4K
- Mark KleinFlowood$3K
- Naveen SandhuFlowood$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.